typhoid conjugate vaccine (EuTCV) compared to Typbar-TCV ®

AlexandrosSfakianakis shared this article with you from Inoreader A Phase II/III, Multicenter, Observer-blinded, Randomized, Non-inferiority and Safety, study of typhoid conjugate vaccine (EuTCV) compared to Typbar-TCV ® in healthy 6 Months-45 years aged participants via Vaccine Vaccine. 2023 Feb 9:S0264-410X(22)01524-9. doi: 10.1016/j.vaccine.2022.12.007. Online ahead of print.ABSTRACTThe typhoid conjugate vaccine (TCV) ensures a long-lasting protective immune response, requires fewer doses and is fit for children under 2 years of age. From Phase I study, EuTCV displayed considerable immunogenicity and reliable safety, thus endorsing further examination in Phase II/III trials. Therefore, a clinical Phase II/III study (NCT04830371) was conducted to evaluate its efficacy in healthy Filipino participants aged 6 months to 45 years through administration of the test vaccine (Arm A, B, and C) or comparator vaccine Typbar-TCV® (Arm D). Sera samples were collect ed pre-vaccination (Visit 1) and post-vaccination (Visit 4, Day 28) to assess the immunogenicity of EuTCV and ... View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.